| Name | Title | Contact Details |
|---|
Healthcare South Pc is a Pembroke, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Frederick Memorial Healthcare System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Frederick Memorial Healthcare System is based in Frederick, MD. You can find more information on Frederick Memorial Healthcare System at www.fmh.org
Terumo Cardiovascular Systems' product line in perfusion circuits is not only one of the most comprehensive in the industry, but also offers an increasing array of products focused on helping surgical teams improve outcomes associated with
Hand & Stone is a 550-plus unit massage and facial spa franchise with a mission to bring affordable, luxury spa services to all. Launched in 2004, the company now has locations across 35 states and Canada. Hand & Stone offers its signature hot stone massage, along with other high-quality professional massage services such as Swedish, Himalayan Salt, Sports, Deep Tissue, Oncology and Prenatal. Guests can also visit the spa to enjoy best-in-class facial treatments performed by licensed estheticians. These feature top-of-the-line products backed by science, including Dermalogica and ClarityRx Clinical Skin Care. A wide range of services are available for women, men and teens and are tailored to each individual`s needs or skin concerns. The fastest-growing spa franchise in the country, Hand & Stone has been named No. 1 in the spa category by Entrepreneur Magazine in 2023, 2021 and 2020 and was ranked No. 8 on Forbes` Best Franchises to Buy list in the high investment category.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.